Document:

Exhibit 10.12
LSA

                      SPONSORED LABORATORY STUDY AGREENIENT

         THIS Agreement is made this __________ day of __________ , 1999,
between The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe
Boulevard, Houston, Texas 77030 ("Institution"), a component of The University
of Texas System ("System"), and B Twelve, Inc., 3303-130 Adelaide Street,
Toronto, Canada M5H 3P5 ("Sponsor"), to conduct a laboratory study and
evaluation ("Study"). Institution and Sponsor agree as follows:

                                   1. PROTOCOL

1.1      Institution agrees to use its best efforts to conduct the Study, as an
         independent contractor, in accordance with Institutional policy,
         applicable laws and regulations and the Project, "Pharmacology of
         Vitamin B 12 Analogs and Antibodies Developed Against Transcobalamin
         and its Cell Receptor" as described in Exhibit A attached hereto and
         incorporated herein. The Study will be supervised by Robert A. Newman,
         Ph.D., (Principal Investigator"), at Institution,- with assistance from
         associates and colleagues as required.

1.2      Sponsor agrees to engage the services of Institution to conduct the
         Study and further agrees to provide at no cost to Institution the
         (samples, drugs, materials) for the conduct of the Study.

                                    2. AWARD

2.1      In consideration for performance of the Study by Institution, Sponsor
         shall pay Institution Eighty- four Thousand and No/100 Dollars
         ($84,000.00) for Study expenses and other related costs. This amount,
         shown by approximate category of expense in Exhibit B attached hereto
         for information only, is payable in four (4) quarterly installments in
         the amount of Twenty-one Thousand and NO/100 Dollars (S21,000.00) each.
         The first payment is payable within thirty (30) days of the date herein
         above.

                                     3. TERM

3.1      This Agreement shall continue in force until the earlier of completion
         of the Study as mutually agreed upon by the parties or twelve (12)
         months from the date set forth above; provided, however, that either
         party may terminate the Agreement by giving thirty (30) days advance
         notice to the other.

3.2      Upon early termination of this Agreement, Sponsor shall be liable for
         all reasonable costs incurred or obligated by Institution at the time
         of such termination, subject to the maximum amount specified in Article
         2. Sponsor shall pay Institution for such costs within thirty (30) days
         of receipt of an invoice for same.

3.3      Upon termination of this Agreement, Institution shall return Sponsor's
         materials and equipment to Sponsor.

<PAGE>
                               4. INDENIYIFICATION

4.1      Institution shall, to the extent authorized under the Constitution and
         laws of the State of Texas, indemnify and hold Sponsor harmless from
         liability resulting from the negligent acts or omissions of
         Institution, its agents or employees pertaining to the activities to be
         carried out pursuant to the obligations of this Agreement; provided,
         however, that Institution shall not hold Sponsor harmless from claims
         arising out of the negligence or willful malfeasance of Sponsor, its
         officers, agents, or employees, or any person or entity not subject to
         Institution's supervision or control. 4.2 Sponsor shall indemnify and
         hold harmless System, Institution, their Regents, officers, agents and
         employees from any liability or loss resulting from judgments or claims
         against them arising out of the activities to be carried out pursuant
         to the obligation of this Agreement, including but not limited to the
         use by Sponsor of the results of the Study; provided, however, that the
         following is excluded from Sponsor's obligation to indemnify and hold
         harmless:

         a.  the negligent * failure of Institution to comply with any
             applicable governmental requirements or to adhere to the terms of
             the Protocol; or

         b.  the negligence or willful malfeasance by a Regent, officer, agent,
             or employee of Institution or System.

                       5. PUBLICATION AND CONFIDENTIALITY

5.1      The parties reserve the right to publish or otherwise make public the
         data resulting from the Study. The party so wishing to publish or make
         public shall submit any such manuscript or release to the other party
         for comment thirty (30) days prior to publication or release.

5.2      Except as otherwise required by law or regulation, neither party shall
         release or distribute any materials or information containing the name
         of the other party or any of its employees without prior written
         approval by an authorized representative of the non-releasing party,
         but such approval shall not be unreasonably withheld.

5.3      Each party shall hold in confidence for three (3) years after the
         termination of this Agreement any confidential information identified
         as confidential and obtained from the other party during the course of
         this Study. Nothing herein, however, shall prevent Institution or any
         other component of System from using any information generated
         hereunder for ordinary research and educational purposes of a
         university.

                            6. LNTELLECTUAL PROPERTY

6.1        Title to all inventions and discoveries made by Institution resulting
           from the research performed hereunder shall reside in Institution;
           title to all inventions and discoveries made by Sponsor resulting
           from the research performed hereunder shall reside in Sponsor; title
           to all inventions and discoveries made jointly by Institution and
           Sponsor resulting from the research performed hereunder shall reside
           jointly in Institution and Sponsor. Inventorship shall be determined
           in accordance with U.S. Patent law.

                                       2
<PAGE>

6.2      After consultation with Sponsor regarding the advisability of filing
         patent applications, Institution shall file appropriate United States
         and foreign patent applications for wholly or jointly owned Institution
         inventions. Institution will provide Sponsor, on a confidential basis,
         a copy of any such application filed and any documents received or
         filed during prosecution thereof and will provide Sponsor the
         opportunity to comment thereon. On any application on which an employee
         of Sponsor is named as a co-inventor, Sponsor will cooperate in
         obtaining execution of any necessary documents by its employees.

6.3      Institution agrees to grant to Sponsor an option to negotiate an
         exclusive, worldwide, royalty bearing license to make, use or sell
         under any invention or discovery owned wholly or partly by Institution
         and made or conceived and reduced to practice during the term of this
         Agreement or within six (6) months thereafter and directly resulting
         from the performance of the research hereunder, with right to
         sublicense with accounting to University. Sponsor shall have three (3)
         months from disclosure of any invention or discovery to notify
         Institution of its desire to enter into such a license agreement, and a
         license agreement shall be negotiated in good faith within a period not
         to exceed siX (6) months from Sponsor's notification to Institution of
         its desire to enter into a license agreement, or such period of time as
         to which the parties shall mutually agree.

6.4      If Sponsor and Institution fail to enter into an agreement during that
         period of time, Sponsor shall have a right of first refusal with
         respect to any terms generally more favorable offered by Institution to
         a third patty for a period of one (1) year thereafter.

6.5      In the event Sponsor elects to exercise its option to negotiate a
         license in accordance with the procedures detailed above, it shall be
         obligated to pay all expenses, including attorney's fees, incurred in
         searching prior art, obtaining search opinions, preparing applications,
         filing, prosecuting, enforcing or maintaining a patent or patent
         application with respect to the licensed invention in any country in
         which the patent or application is filed.

                                   7. GENERAL

7.1      This Agreement, including the attached Exhibit A and B, constitutes the
         entire and only Agreement between the parties relating to the Study,
         and all prior negotiations, representations, agreements, and
         understandings are superseded hereby. No agreements altering or
         supplementing the terms hereof, including the exhibits attached hereto,
         may be made except by a written document signed by the duly authorized
         representatives of the parties.

7.2      Any conflicts between the Protocol and this Agreement are controlled by
         this Agreement.

7.3      This Agreement shall be construed and enforced in accordance with the
         laws of the State of Texas.

7.4      This Agreement anticipates educational training and may involve health
         science postgraduates and other students of the Institution.

                                       3
<PAGE>

         IN WITNESS WHEREOF, Institution and Sponsor hereby enter into this
Agreement, effective as of the date first set forth above, and execute two (2)
original counterparts.

Sponsor                                 The University of Texas
                                        M.D. Anderson Cancer Center

By: /s/ Uri Sagman                      By: /s/ Carleen Brunelli
    -------------------------               ------------------------------------
        Uri Sagman                              Carleen Brunelli, Ph.D., M.B.A.
Title: President                                Executive Director,
Date: Aug. 31, 1999                             Research Administration
                                        Date: 8-25-99

                                              I have read this agreement and
                                              understand my obligations
                                              hereunder:

                                        By: /s/ Robert A. Newman
                                            ------------------------------------
                                                Robert A. Newman, Ph.D.
                                                Principal Investigator

                                        By: /s/ Robert C. Bast
                                            ------------------------------------
                                                Robert C. Bast, Jr., M.D.
                                                Head, Division of Medicine

Make Payment to:
The University of Texas
M.D. Anderson Cancer Center
Attn: Manager, Grants and Contracts Accounting
P.O. Box 297402
Houston, TX 77297
Tax I.D. 74 6001118 A1

                                       4EXHIBIT 10.13

                           AMENDMENT No. 1 TO RESEARCH

                                    AGREEMENT

This Amendment No. I to Research Agreement ("Amendment") is made and entered
into as of November 20, 2000 by and between B-Twelve, Inc. ("Sponsor") and The
University of Texas M.D. Anderson Cancer Center ("Institution"), a component of
the University of Texas System ("System").

                                                      RECITALS

A.       Sponsor and Institution entered into a Sponsored Research Agreement
         dated August 31, 1999 (the "Agreement").

B.       Sponsor and Institution wish to amend the terms of the Agreement as set
         forth below.

 NOW, THEREFORE, it is hereby agreed as follows:

1.       Section 2 of the Agreement shall be revised to read in its entirety as
         follows:

         "In consideration for performance of the Study by Institution, Sponsor
         shall pay Institution Eighty four Thousand and no/100 Dollars
         (S84,000.00) for Study related costs expenses and other costs. This
         amount shall be payable in four quarterly installments in the amount of
         Twenty-one Thousand and no/100 Dollars (521,000.00) each. The first
         payment has been made. The second payment is payable by December 31,
         2000. "

2.       Section 3.1 of the Agreement shall be revised to read in its entirety
         as follows:

         This Agreement shall continue in force until the earlier of completion
         of the Study as mutually agreed upon by the parties or until October
         31, 2001; provided, however, that either party may terminate the
         Agreement by giving thirty (30) days advance notice to the other."

3.       Except as expressly provided in this Amendment, all other terms,
         conditions and provisions of the Agreement shall continue in full force
         and effect as provided therein.

                    THIS SECTION IS INTENTIONALLY LEFT BLANK.

<PAGE>

IN WITNESS WHEREOF, Sponsor and Institution have entered into this Amendment
effective as of the date first set forth above.

B-TWELVE, INC.                        THE UNIVERSITY OF TEXAS
                                      M.D. ANDERSON CANCER CENTER

By /s/ Uri Sagman                     By /s/Leonard S. Zwelling
   ---------------------------           -----------------------------
Uri Sagman, M.D., FRCPC               Leonard A. Zwelling, M.D., M.B.A.
President and CEO                     Vice President for Research Administration

Date: Nov. 20, 2000                   Date: 11/27/00
     -------------------------              --------------------------

                                      I have read this Amendment and understand
                                      my obligations hereunder:

                                      /s/Robert A. Newman
                                      ---------------------------------
                                      Robert A. Newman, Ph.D.
                                      Principal Investigator

                                      /s/Thomas D. Brown, M.D.
                                      ----------------------------------
                                      Thomas D. Brown, M.D.
                                      Head Ad Interim, Division of Cancer
                                      Medicine

                                      Reviewed and Approved
                                      /s/R. Moore
                                      ------------------------------------
                                      Date:  11-21-00
                                             -----------------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}]]